 
 
  
   
MDT17025SIG  
 
A prospective, two -arm, multicenter, post market study to  
confirm the safety and performance of the Signia™ Stapling  
System using Endo GIA™ Reloads with Tri -Staple™ Technology 
and 
Tri-Staple™ 2.0 Intelligent Reloads in abdominal and thoracic  
procedures.  
 
 
[STUDY_ID_REMOVED]  
 
Study Protocol, 10 -AUG -2018  
Signed By Meaning of Signature Date/Time (UTC)APPROVALSCONFIDENTIAL  
DOCUMENT/RECORD   
 
This document/record is electronically controlled; printed copies are considered uncontrolled. 
System of Record: Regulatory Affairs Domain   
Document Name Version
Title
Document Approver
Document Approver
Document Approver
08/29/2018 14:09:59
3.0
08/27/2018 15:27:16
Disalvo, Michelle
Ver 3.0 2018 08 10
Document Approver
Mauro, Christine
08/29/2018 13:39:15
Hopp, Colleen
08/22/2018 19:48:09
Lourd, Mathilde
Lyons, Patrick
Document Approver
Document Approver
08/23/2018 18:34:59
Loeser, Beverlee
08/29/2018 12:43:47
Sindberg, Greg
Frydlewski, Shoshana
08/22/2018 19:50:07
08/22/2018 20:01:40
Document Approver
Document Approver
CIP Signia MDT17025SIG

Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 1 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
   
Clinical Investigation Plan  
Clinical Investigation Plan/Study 
Title  A prospective, two -arm, multicenter, post market study to 
confirm the safety and performance of the Signia ™ Stapling 
System using Endo GIA™  Reloads with Tri-Staple™  Technology and 
Tri-Staple™ 2.0 Intelligent Reloads  in abdominal and thoracic 
procedures.  
Clinical Investigation Plan 
Identifier  MDT17025SIG  
Study Product Name  Signia™ Stapling System using Endo GIA™  Reloads with Tri-
Staple™  Technology and Tri-Staple™ 2.0 Intelligent Reloads  
Sponsor/Local Sponsor  Sponsor:  
Covidien -Medtronic  
Minimally Invasive Therapies Group  
Surgical Innovations  
15 Hampshire St.  
Mansfield MA 02048  
 
Local Sponsor:  
Covidien Services Europe (an indirect, wholly owned subsidiary of 
Medtronic plc.)  
Medtronic PLC,  
Block 3090 -3094, Lake Drive, Citywest Business Campus,  
Co. Dublin, D24 XN47, Ireland  
Document Version  3.0, 10-Aug-2018 
Confidentiality Statement  
The information  contained  in this document  is confidential  and the proprietary  property  of 
Medtronic.  Any distribution,  copying,  or disclosure  without  the prior  written  authorization  of 
Medtronic  is strictly  prohibited.  Persons  to whom  the information  is disclosed  must  know that it is 
confidential  and that it may  not be further  disclosed  by them.  
  

Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 2 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  1. Investigator Statement  
Study product Name  Signia™ Stapling System using Endo GIA™  Reloads with 
Tri-Staple™  Technology and Tri-Staple™ 2.0 Intelligent 
Reloads  
Sponsor  Sponsor:  
Covidien -Medtronic  
Minimally Invasive Therapies Group  
Surgical Innovations  
15 Hampshire St.  
Mansfield MA 02048  
 
Local Sponsor:  
Covidien Services Europe (an indirect, wholly owned 
subsidiary of Medtronic plc.)  
Medtronic PLC,  
Block 3090 -3094, Lake Drive, Citywest Business Campus,  
Co. Dublin, D24 XN47, Ireland  
Clinical Investigation Plan Identifier  MDT17025SIG  
Version Number/Date  3.0, 10-Aug-2018  
I have read the protocol, including all appendices, and I agree that it contains all necessary details for 
me and my staff to conduct this study as described. I will conduct this study as outlined herein and 
will make a reasonable effort to complete the study within the time designated.  
I agree to comply with United Stated Foo d and Drug Administration (USA) or ISO 14155:2011 (EU) 
regulations under which the study is being conducted.  I agree to ensure that the confidential 
information contained in this document will not be used for any purpose other than the evaluation 
and condu ct of the clinical investigation without the prior written consent of Medtronic.  
I will provide all study personnel under my supervision copies of the protocol and access to all 
information provided by Medtronic. I will discuss this material with them to e nsure that they are fully 
informed about the products and the study.  
Investigator’s Signature:   
Investigator’s Name:   
Institution:   
Date:    
  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 3 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Table of Contents  
 
1. Investigator Statement  ................................ ................................ ................................ ...... 2 
Table of Contents  ................................ ................................ ................................ ......................  3 
2. Glossary  ................................ ................................ ................................ ..............................  7 
3. Synopsis  ................................ ................................ ................................ ...........................  10 
4. Introduction  ................................ ................................ ................................ .....................  17 
4.1. Background  ................................ ................................ ................................ ...........................  17 
4.2. Purpose  ................................ ................................ ................................ ................................ . 17 
5. Objectives an d Endpoints  ................................ ................................ ................................ . 18 
5.1. Objectives  ................................ ................................ ................................ .............................  18 
5.1.1.  Primary Objective(s)  ................................ ................................ ................................ ..............  18 
5.1.2.  Secondary Objective(s) ................................ ................................ ................................ ..........  18 
6. Study Design  ................................ ................................ ................................ ....................  19 
6.1. Duration  ................................ ................................ ................................ ................................  19 
6.2. Rationale  ................................ ................................ ................................ ...............................  20 
6.3. Selection of Investigators  ................................ ................................ ................................ ....... 20 
7. Product Description ................................ ................................ ................................ ..........  20 
7.1. General  ................................ ................................ ................................ ................................ . 20 
7.1.1.  Signia™ S tapler  ................................ ................................ ................................ ................  21 
7.1.2.  Signia™ Accessories  ................................ ................................ ................................ ...............  22 
7.1.3.  Number of Devices to be Used  ................................ ................................ .............................  23 
7.2. Manufacturer  ................................ ................................ ................................ .........................  23 
7.3. Packaging  ................................ ................................ ................................ ..............................  23 
7.4. Intended Population  ................................ ................................ ................................ ...............  23 
7.4.1. Indications for Use  ................................ ................................ ................................ ...........  24 
7.5. Equipment  ................................ ................................ ................................ .............................  25 
7.5.1.  Endo GIA™ with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads (single -use)
 25 
7.6. Product Use  ................................ ................................ ................................ ...........................  25 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 4 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  7.7. Product  Training Requirements  ................................ ................................ ...............................  25 
7.8. Product Receipt and Tracking  ................................ ................................ ................................ . 26 
7.9. Product Storage  ................................ ................................ ................................ .....................  26 
7.10.  Product Return  ................................ ................................ ................................ .................  26 
7.11.  Product Accountability  ................................ ................................ ................................ ...... 26 
8. Selection of Subjects  ................................ ................................ ................................ ........  27 
8.1. Study Population  ................................ ................................ ................................ ....................  27 
8.2. Subject Enrollment  ................................ ................................ ................................ .................  27 
8.3. Inclusion Criteria  ................................ ................................ ................................ ....................  27 
8.4. Exclusion Criteria  ................................ ................................ ................................ ...................  28 
9. Study Procedures  ................................ ................................ ................................ .............  29 
9.1. Schedule of Events  ................................ ................................ ................................ .................  29 
9.1.1.  Study schematic  ................................ ................................ ................................ ....................  29 
9.2. Subject Screening  ................................ ................................ ................................ ..................  30 
9.3. Prior and Concomitant Medications  ................................ ................................ .........................  30 
9.4. Subject Consent  ................................ ................................ ................................ .....................  31 
9.5. Randomization and Treatment Assignment  ................................ ................................ ..............  31 
9.6. Medication Compliance  ................................ ................................ ................................ ...........  31 
9.7. Assessment of Efficacy  ................................ ................................ ................................ ...........  31 
9.7.1.  Operative (Day 0) ................................ ................................ ................................ .............  32 
9.7.2.  Discharge Assessment  ................................ ................................ ................................ ...... 33 
9.7.3.  Follow -up Assessments (Day 30 +14 days))  ................................ ................................ ....... 33 
9.8. Assessment of Safety  ................................ ................................ ................................ .............  34 
9.9. Recording Data  ................................ ................................ ................................ ......................  34 
9.10.  Deviation Handling  ................................ ................................ ................................ ...........  34 
9.11.  Subject Withdrawal or Discontinuation  ................................ ................................ ...............  35 
9.11.1.  Enrolled  ................................ ................................ ................................ ........................  35 
9.11.2.  Screen Failure  ................................ ................................ ................................ ...............  35 
9.11.3.  Discontinuation  ................................ ................................ ................................ .............  35 
9.11.4.  Withdrawal  ................................ ................................ ................................ ...................  35 
9.11.5.  Lost to Follow -up ................................ ................................ ................................ ..........  35 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 5 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  10. Risks and Benefits  ................................ ................................ ................................ .........  36 
10.1.  Potential Risks  ................................ ................................ ................................ ..................  36 
10.2.  Potential Benefits  ................................ ................................ ................................ .............  37 
10.3.  Risk-Benefit Rationale  ................................ ................................ ................................ ....... 37 
11. Adverse Events and Device Deficiencies  ................................ ................................ ....... 37 
11.1.  Definitions/Classifications  ................................ ................................ ................................ .. 38 
11.1.1.  Adverse Event (AE)  ................................ ................................ ................................ ....... 38 
11.1.2.  Serious Adverse Events (SAE)  ................................ ................................ ........................  38 
11.1.3.  Adverse Device Effect (ADE)  ................................ ................................ ..........................  39 
11.1.4.  Serious Adverse Device Effect (SADE)  ................................ ................................ ............  39 
11.1.5.  Unanticipated Serious Adverse Device Effect (USADE)  ................................ .....................  39 
11.1.6.  Device Deficiencies  ................................ ................................ ................................ ....... 40 
11.1.7.  Adverse Event Severity Classification  ................................ ................................ ..............  40 
11.1.8.  Adverse Event Relationship Classification  ................................ ................................ ........  40 
11.1.9.  Adverse Event Outcome Classification  ................................ ................................ ............  42 
11.2.  Reporting of Adverse Events  ................................ ................................ .............................  42 
11.3.  Study Contact Information  ................................ ................................ ................................  45 
12. Data Review Committees  ................................ ................................ ..............................  46 
12.1.  Safety Committee  ................................ ................................ ................................ .............  46 
12.2.  Independent Medical Monitor  ................................ ................................ ............................  46 
12.3.  Steering Committee  ................................ ................................ ................................ ..........  46 
13. Statistical Design and Methods  ................................ ................................ .....................  46 
13.1.  Statistical Test Methods  ................................ ................................ ................................ .... 46 
13.2.  Sample Size Determination  ................................ ................................ ...............................  47 
13.3.  Analysis Population  ................................ ................................ ................................ ...........  47 
13.4. Statistical Analysis Endpoints ................................ ................................ .............................  48 
13.4.1.  Primary Endpoint  ................................ ................................ ................................ ..........  48 
13.4.2.  Secondary Endpoint  ................................ ................................ ................................ ...... 48 
13.5.  Handling of Missing Data  ................................ ................................ ................................ .. 48 
13.6.  Interim Analysis  ................................ ................................ ................................ ...............  48 
14. Ethics  ................................ ................................ ................................ .............................  49 
14.1.  Statement(s) of Compliance  ................................ ................................ ..............................  49 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 6 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  15. Study Administration  ................................ ................................ ................................ ..... 49 
15.1. Monitoring  ................................ ................................ ................................ .......................  49 
15.2.  Data Management  ................................ ................................ ................................ ............  50 
15.3.  Direct Access to Source Data/Documents  ................................ ................................ ...........  50 
15.4.  Confidentiality  ................................ ................................ ................................ ..................  50 
15.5.  Liability  ................................ ................................ ................................ ............................  51 
15.6.  CIP Amendments  ................................ ................................ ................................ .............  51 
15.7.  Record Retention  ................................ ................................ ................................ .............  51 
15.8.  Publication and Use of Information  ................................ ................................ ....................  51 
15.9.  Suspension or Early Termination  ................................ ................................ .......................  52 
16. References  ................................ ................................ ................................ .....................  53 
17. Version History  ................................ ................................ ................................ ..............  53 
18. Appendices  ................................ ................................ ................................ ....................  55 
18.1.  APPENDIX  A: Endo GIA™ with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads
 55 
18.2.  APPENDIX B: American Society of Anesth esiologists (ASA) Physical Status Grading System  .. 56 
18.3.  APPENDIX C: List of Investigators and Institutions  ................................ .............................  57 
 
  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 7 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  2. Glossary  
Term  Definition  
ADE Adverse device effect - Adverse event related to 
the use of an investigational medical device.  
Note: This definition includes adverse events 
resulting from insufficient or inadequate 
instructions for use, deployment, implantation, 
installation, or operation or any malfunction of 
the investigational medical device.  
Note: This definition includes any event resulting 
from u se error or from intentional misuse of the 
investigational medical device.  
See Clinical Event definition for more 
information.  
AE Adverse event - Any untoward medical 
occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal 
laboratory findings) in subjects, users or other 
persons, whether or not related to the 
investigational medical device.  
Note: This  definition includes events related to 
the investigational medical device or the 
comparator.  
Note: This definition includes events related to 
the procedures involved.  
Note: for users or other persons, this definition is 
restricted to events related to inve stigational 
medical devices.  
See Clinical Event definition for more 
information.  
ASA American Society of Anesthesiologists  
BMI Body mass index (kg/m2) - BMI is a person's 
weight in kilograms (kg) divided by his or her 
height in meters squared.  
CC Cubic centimeter (liquid volume)  
CIP Clinical Investigation Plan (can be used 
synonymously with Protocol)  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 8 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Term  Definition  
COPD  Chronic obstructive pulmonary disease - a 
chronic condition in which there is a slow, 
progressive obstruction of a irflow into or out of 
the lungs  
Device Deficiency  Inadequacy of a medical device with respect to its 
identity, quality, durability, reliability, safety or 
performance.  
Note: Device deficiencies include malfunctions, 
use errors, and inadequate labeling.  
See Clinical Event definition for m ore 
information.  
eCRF  Electronic Case Report Form  
ICJME  International Committee of Medical Journal 
Editors  
IFU Instructions for use  
ISO International Organization for Standardization  
ITT Intent -to-treat  
LCD Liquid crystal display  
LED Light emitting diode  
LRYGB  Laparoscopic Roux -en-Y gastric bypass – A type of 
weight loss surgery that reduces the size of the 
upper stomach to a small pouch by stapling off 
the upper section of the stomach then attaches 
this pouch directly to part of the small intestine  
called the Roux limb forming a “Y” shape.  
LSG Laparoscopic sleeve gastrectomy  – A laparoscopic 
surgical weight -loss procedure in which the 
stomach is reduced , by surgical removal of a large 
portion of the stomach along the greater 
curvature  resulting in a sleeve or tube -like 
structure  
MedDRA  Medical Dictionary for Regulatory Activities  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 9 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Term  Definition  
OLED  Organic light emitting diodes  
RDC Remote data capture  
SAE Serious Adverse Event  - Adverse event that:  
a. Led to a death,  
b. Led to a serious deterioration in the 
health of the subject, that either resulted 
in: 
1. Resulted in a life threatening illness 
or injury, or  
2. Resulted in a permanent impairment 
of a body structure or a body 
function, or  
3. In-patient or prolonged 
hospitalization, or  
4. Medical or surgical intervention to 
prev ent life threatening illness or 
injury or permanent impairment to a 
body structure or a body function, or  
c. Led to fetal distress, fetal death or a 
congenital abnormality or birth defect.  
Note: Planned hospitalization for a pre -existing 
condition, or a proce dure required by the CIP, 
without serious deterioration in health, is not 
considered a serious adverse event.  
SADE  Serious Adverse Device Effect  - Adverse device 
effect that has resulted in any of the 
consequences characteristic of a serious adverse 
event . 
USADE  Unanticipated Serious Adverse Device Effect - 
Any serious adverse device effect which by its 
nature, incidence, severity or outcome has not 
been identified in the current version of the risk 
analysis report.   
Note: Anticipated serious adverse device effect 
(ASADE) is an effect which by nature, incidence, 
severity or outcome has been identified in the 
risk analysis report.  
VATS  Video assisted thoracic surgery  
  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 10 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  3. Synopsis  
Title  A prospective, two -arm, multicenter, post market study to confirm 
the safety and performance of the Signia™ Stapling System using 
Endo GIA™  Reloads with Tri-Staple™  Technology and Tri-Staple™ 2.0 
Intelligent Reloads  in abdominal and thoracic procedures.  
Clinical Study Type  Post -market, prospective, two -arm, multi -center  
Product Name  Signia™ Stapling System using Endo GIA™  Reloads with Tri-Staple™  
Technology and Tri-Staple™ 2.0 Intelligent Reloads  
Sponsor  Covidien -Medtronic  
Minimally Invasive Therapies Group  
Surgical Innovations  
15 Hampshire St.  
Mansfield MA 02048  
Loca l Sponsor  Covidien Services Europe (an indirect, wholly owned subsidiary of 
Medtronic plc.)  
Medtronic PLC,  
Block 3090 -3094, Lake Drive, Citywest Business Campus,  
Co. Dublin, D24 XN47, Ireland  
Indication under 
investigation  Abdominal and thoracic procedures for resection, transection and 
creation of anastomosis  per the instructions for use (IFU)  
Product Status  Signia™ Stapling System  
• Food and Drug Administration (FDA) 510K cleared (US A) 
• CE Mark approval (EU), Self -Declared  
 
Primary Objective(s)  The objectives of this prospective, two -arm, multicenter post -market 
study is to confirm safety and performance through the incidence of 
subjects reporting serious  adverse device effects (ADEs) up to and 
including 30  (+14)  days  follow ing use of Signia™ Stapling System with 
Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 
Intelligent Reloads  in subjects undergoing indicated abdominal or 
thoracic procedures  for resection, transection and creation of 
anastomosis per the IFU .  
Secondary Objective(s)  The secondary  endpoint is device deficiency/malfunctions affecting 
the intended performance of the device to include;  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 11 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • Staple line assessment:  
o Intraoperative assessments:  
▪ Assessment of staple line integrity  
▪ Incidence of staple line bleeding (measured 
as ≥ 50 cc ) 
▪ Additional intervention(s) to treat staple -line 
failure (ex: glue, manual over sew, Medtronic 
buttress ) or intraoperative 
revision/recreation of the anastomosis  
▪ Incidence of leakage (as measured by ai r leak 
test, or standard of care, as applicable)  
o Post -operative assessments:  
▪ Duration of air leakage (in days) for thoracic 
procedures  
• Prolonged air leaks are considered >7 
days  
▪ Incidence of leakage for abdominal 
procedures as evidenced confirmed by 
imagi ng, subject presentation or decline in 
status, or need for reoperation/re -
intervention  
▪ Incidence of post -operative infection  
assessed by the Investigator according to the 
standard of care and site policy, ex. Positive 
wound culture  
▪ Additional intervention( s) to treat staple -line 
failure  
• Incidence of repeat hospital admissions for primary 
procedure -related complications . 
 
All recorded device deficiencies/malfunctions will be captured and 
assessed by the Investigator. Complaints will be handled in 
accordance with the standard procedures for the post -market 
vigilance system.  
Randomization  There will be no randomization used for this study  
Sample Size  A minimum  of 127  subjects will be enrolled under 2 study arms, 
(abdominal or thoracic) at approximately 10 sites  in the USA and 
Europe  (potentially in United Kingdom, Spain, Italy) .  
• Abdominal (approximately 53 subjects)  
• Thoracic (approximately 74 subjects)  
Inclusion/Exclusion Criteria  Inclusion Criteria  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 12 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  1. Adults (male or female) between 22 and 80 years of age 
inclusive at the time of the procedure.  
2. The subject must be willing and able to participate in the 
study procedures and to understand and sign the informed 
consent.  
3. The subject is scheduled to undergo an indicated primary 
abdominal or thoracic procedure fo r resection, transection 
and creation of anastomosis per the IFU where the Signia™ 
Stapling System with Endo GIA™  with Tri -Staple™ Technology 
and Tri -Staple™ 2.0 Intelligent Reloads  will be used per its IFU. 
Additionally, if considered appropriate for the procedure only 
Medtronic buttresses can be used during the course of the 
study.  
a. Thoracic procedures may include, but are not limited 
to wedge resection and lobectomy, and may include 
video assisted thoracic surgery (VATS) or open 
procedures  
b. Abdominal procedures may include, but are not 
limited to, laparoscopic sleeve gastrectomy (LSG), 
laparoscopic Roux -en-Y gastric bypass (LRYGB)  
Exclusion Criteria  
1. Subjects undergoing cardiac and vascular procedures  
2. The procedure is an emergency procedure  
3. The procedur e is a revision/reoperation of a primary 
operation  
4. Any female subject who is pregnant  
a. Females of child -bearing potential will be required to 
undergo either a urine pregnancy test or serum 
pregnancy test during Screening and confirmed on 
the day of operatio n (except for subjects who are 
surgically sterile or are post -menopausal for at least 
two years) (USA only) and per EU local requirements  
5. Any subject who is considered to be part of a vulnerable 
population (e.g. prisoners or those without sufficient menta l 
capacity)  
6. The subject is unable or unwilling to comply with the study 
requirements or follow -up schedule  
7. The subject has comorbidities which, in the clinical judgment 
of the Investigator, will not be appropriate for the study or 
the subject has an estima ted life expectancy of less than 6 
months  
8. The subject has been diagnosed with a bleeding disorder 
and/or is undergoing active and not reversed anticoagulant 
treatment.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 13 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  9. The subject is concurrently enrolled in another investigational 
drug or device research study or has been enrolled in another 
study within 30 days of enrollment.  
10. Pre-existing/chronic conditions specific to Tri -Staple™ 2.0 
Reload contraindications as described in the IFU.    
Study Procedures and 
Assessments  Subjects will be evaluated at screening, day of operative visit, 
discharge, and 30 (+14) days post -operative.  
Assessments to be conducted/data collected include:  
 
Screening:  
• Eligibility Criteria  
• Subject demographics (e.g., sex, age, ethnicity and race if 
allowed per local regulations)  
• Medical and surgical history (p revious abdominal or thoracic 
surgical history , smoking history, anticoagulant therapies and 
prevalence of diabetes)  
• Vital signs ( heart rate, temperature, respiratory rate, blood 
pressure)  
• Oxyge n saturation levels  
• BMI 
• Abbreviated physical exam, including height, weight, and 
examination of the heart, lung, and abdomen  
• Serum or urine pregnancy test females of child bearing 
potential ( USA only) or per EU local requirements  
 
Operative Visit:  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 14 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • Eligibility  Criteria * 
• Vital signs ( heart rate, temperature, respiratory rate, blood 
pressure, pulse , oxygen saturation levels )* 
• Abbreviated physical exam, including height, weight, and 
examination of the heart, lung, and abdomen*  
• American Society of Anesth esiologists (ASA) grade (See 
Appendix B, Section 18.2)  
• Serum or urine pregnancy test females of child bearing 
potential ( USA only) or per EU local requirements *  
* Assessments only need to be repeated if Screening/Operative Visit 
occur on different days  
• Operative date  
• Operative start (skin incision) and stop times (skin closure)  
• Type of procedure  
• General anesthesia information (type, start and stop times)  
• Study device data (i.e.,  type of reload used, staple size,  lot 
number of devices used,  number of firing s, location of firings ) 
• Use of Signia feedback display  during surgery  (if applicable)  
• Relevant concomitant medications (only those related to 
relevant medical history or adverse events will be collected 
e.g.: anticoagulants, blood pressure, antibiotics, pa in 
medications)  
• Procedure related adverse events and adverse device effects 
(ADEs)  
• Staple line assessment  
• Device deficiencies/malfunctions affecting intended 
performance to include  but not limited to ;  
o System set -up (insertion guide, power shell)  
o Organic light emitting diode (OLED) screen display  
o Rotation  
o Articulation  
o Clamp/UnClamp  
o Firing  
o Use of manual retraction tool  
o User errors  
o Unintended cutting  
o Insufficient staple deployment  
o Inability to complete the firing sequence  
o Stapling without cutting  
• Device acco untability  
 
Discharge Assessments:  
• Procedure related adverse events and adverse device effects  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 15 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • Length of hospital stay  
• Length of intensive care unit stay (if applicable)  
• Surgical site and infection assessment by the Investigator 
according to the standard of care and site policy, ex. Positive 
wound culture  
• Relevant concomitant medications (only those related to 
relevant medical history or adverse events will be collected 
e.g.: anticoagulants, blood pressure, antibiotics, pain 
medications)  
 
Follow -up Assessm ents (Post -operative day 30 (+14)):  
• Readmission  related to primary procedure  
• Procedure related adverse events  
• Advers e device effects (ADEs)  
• Surgical site and infection assessment  by the Investigator 
according to their the standard of care and site policy,  ex. 
Positive wound culture  
• Relevant concomitant medications (only those related to 
relevant medical history or adverse events will be collected 
e.g.: anticoagulants, blood pressure, antibiotics, pain 
medications)  
 Statistics  Sample Size Determination  
 
Sample size was determined based on the primary  endpoint 
(incidence of subjects report ing serious  adverse device effects up to 
and including 30 days (+14 days) post -procedure ) and considering an 
acceptable probability (≥ 80%) to observe at least one adverse  device 
effect within 30 days, in each arm (abdominal or thoracic indication).  
  
A previous Medtronic study (ClinicalTrials.gov ID   [STUDY_ID_REMOVED]) 
conducted on N=100 subjects and evaluating an equivalent device 
(Endo GIA™ Reinforced Reload with Tri -Staple™ T echnology) in the 
same indications and with a similar design and follow -up reported the 
following adverse device effect rates (described as “device related 
adverse events” with the study protocol and final report):  
 
  Abdominal  Thoracic  
Adverse device effect incidence  3.3%  2.5% 
 
Because of the expected low adverse device effect incidence rate 
(<5%) in the Abdominal or Thoracic procedures, as described above, a 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 16 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Poisson distribution is applied to estimate the probability of observing 
AE event(s).  
 
In the Abdominal indication, for an anticipated sample size of 53 
subjects using an adverse device effect rate of 3.3%, and including a 
5% attrition rate within 30 days , we obtain a probability of 81% to 
observe at least 1 adverse device effect.  
 
In the Thoracic indication, for an anticipated sample size of 7 4 
subjects using an adverse device effect rate of 2.5%, and including a 
5% attrition rate within 30 days , we obtain a probability of 83% to 
observe at least 1 adverse device effect.  
 
For the overall population (in both indications), with a sample size of 
127 subjects considering an averaged adverse device effect rate of 
2.9%  and an attrition rate of 5% within 30 days , we obtain a 
probability of 97% to observe at least 1 adverse device effect, and a 
probability of 86% to observe at least 2 adverse device effects.  
 
In any scenario, we will have ≥ 80% probability to observe at least 1 
adverse device effect in each arm.  
 
Primary Endpoint Analysis  
The primary endpoint is the incidence of subjects r eporting serious 
adverse device effects up to and including 30 da ys (+14 days) postop . 
It will be summarized using descriptive statistics.  
A two -sided 95% confidence interval will also be calculated.  The 
acceptance criteria for this endpoint is an upper limit of the 95% CI 
below 20%.  
The analysis will be performed in abdominal group and in thoracic 
group, and in the combined groups.  
 
Secondary  Endpoint Analysis  
The incidence of secondary outcome measures will be summarized 
using descriptive statistics:  
• counts and percentages for categorical data  
mean, standard deviation, median, minimum and maximum for 
quantitative data.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 17 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Interim Analysis   A preliminary analysis will be conducted in the study when a total of 
64 subjects have been enrolled and completed  the 30 day follow up 
visits.   
4. Introduction  
4.1. Background  
During abdominal and thoracic procedures, staple line failure can result in severe intraoperative and 
postoperative complications. After thoracic lung resection, postoperative air leaks are the most common 
complication with a reported occurrence between 4%  and 58% [1-5]. In patients with concomitant 
chronic obstructive pulmonary disease (COPD) and fused fissures these rates can climb as high as 90% 
[6]. Thoracic air leak complications can include reduced mobility, increased hospital stay, the need for 
longer chest tube time (o ften associated with increased pain), and risk of further complications [1]. 
With the exception of staple lines across a distal obstruction or severe ileus, leaks are less common 
during gastrointestinal surgery due to lower intraluminal pressures to which the staple lines are 
exposed. If leaks do occur ; however , the complications can be severe. Postoperative leak rates following 
laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux -en-Y gastric bypass (LRYGB) have been 
reported between 1% and 3% and leak -associa ted mortality has been reported at 0.1% [7-11].  
Clearly, the integrity of the staple line is a primary factor in the creation of a stable anastomosis. The 
various characteristics of each tissue type present unique challenges and until now the firing speed used 
during these procedures was determined by the surgeon, particularly when using a  manual firing setup 
[12]. Ultimately relying on generation of the ideal ‘B’ shaped staples, surgeon experience played a 
crucial role in effective staple line production [13, 12] .  
The Signia™ Sta pling System with Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent 
Reloads  uses a single -use reload. Automatically adjusting firing speed to optimize staple formation using 
an onboard intelligence, the Signia™ Stapling System generates  consistent staple lines and real -time 
surgeon feedback via an OLED display. Additionally,  the Signia™ Stapling System can be used single 
handed. To date single -handed use has proved challenging for many surgeons using manual firing 
systems.  
4.2. Purpose  
The p urpose of this study is to confirm the safety and performance of the Signia™ Stapling System with 
Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  in a minimum of 127 
enrolled subjects undergoing indicated abdominal or thoracic  procedures enrolled at approximately 10 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 18 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  sites  in the US A and Europe ( potentially in the United Kingdom, Spain, Italy ). At the conclusion of the 
study, data will be submitted for publication.   
5. Objectives and Endpoints  
5.1. Objectives  
The objective of this prosp ective, two -arm, multicenter post -market study is to confirm safety and 
performance through the incidence of subjects reporting serious  adverse device effects (ADEs, as 
defined by ISO14155:2011, see section 11.1.3 for additional details) up to and includin g 30  (+14)  days  
following use of Signia™ Stapling System with Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 
2.0 Intelligent Reloads  in subjects undergoing indicated abdominal or thoracic procedures. (See Section 
18.1 Appendix A, for Reloads  to be assessed  in this study)  
5.1.1.  Primary Objective(s)  
The primary  endpoint is the incidence of subjects reporting  serious adverse device effects (ADEs) up to 
and including  the 30 day  (+14 day) post -operative  follow up visit  including intra - and post -operative 
leaks. The causes of these leaks will be documented when available.  
5.1.2.  Secondary Objective(s)  
The secondary  endpoint is device deficiency/malfunction affecting the intended performance of the 
device to include;  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 19 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • Staple line assessment:  
o Intraoperative assessments:   
▪ Assessment of staple line integrity  
▪ Incidence of staple line bleeding (measured as ≥ 50 cc)  
▪ Additional intervention(s) to treat staple -line failure (ex: glue, manual over sew, 
Medtronic buttress) or intraoperative revision/recreation of the a nastomosis  
▪ Incidence of leakage (as measured by air leak test, or standard of care, as 
applicable)  
o Post -operative assessments:  
▪ Duration of air leakage (in days) for thoracic procedures  
• Prolonged air leaks are considered >7 days  
▪ Incidence of leakage for ab dominal procedures as evidenced confirmed by 
imaging subject presentation or decline in status, or need for reoperation/re -
intervention  
▪ Incidence of post -operative infection, assessed by the Investigator according to 
the standard of care and site policy, e x. positive wound culture  
▪ Additional intervention(s) to treat staple -line failure  
• Incidence of repeat hospital admissions for primary procedure -related complications.  
 
All recorded device deficiencies/malfunctions will be captured and assessed by the Inves tigator. 
Complaints will be handled in accordance with the standard procedures for the post -market vigilance 
system.  
6. Study Design  
The purpose of this study is to confirm the safety and performance of the Signia™ Stapling System with 
Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  in a minimum of 127 
enrolled subjects undergoing indicated abdominal or thoracic procedures enrolled at approximately 10  
sites in the US A and Europe ( potentially in the United Kingdom, Spain, Italy ).  
6.1. Duration  
Including enrollment/screening and follow -up time for all enrolled subjects the study is estimated to 
progress for up to 24 months. Not including hospital stay (which could vary depending on the 
procedure), s ubjects will participate for potentially  74 days. Screening for eligibility may occur 30 days 
(inclusive) prior to the procedure. Post -procedure, subjects will be assessed for incidence of adverse 
device effect events up to and including  the 30 day  (+14 da y) post -operative  follow up visit .  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 20 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  6.2. Rationale  
In order to assess the clinical safety of the Signia™ Stapling with Endo GIA™  with Tri -Staple™ Technology 
and Tri -Staple™ 2.0 Intelligent Reloads , Medtronic is performing a prospective, two -arm, multicenter, 
post-market study on adult subjects undergoing abdominal or thoracic procedures using the device and 
appropriate Reloads (See Appendix A). During the procedure device deficiencies affecting the intended 
performance of the device will be collected and inciden ce of reported adverse device effects will be 
assessed up to and including  the 30 day  (+14 day) post -operative follow up visit following the procedure. 
This study does not utilize any randomization or blinding. Currently there are no known factors that may  
compromis e study outcomes or the interpretation of results (e.g., baseline characteristics, concomitant 
medications, the use of other study products, or subject -related factors such as age, gender or lifestyle). 
If any adverse device effect occurrences ar e identifi ed they will be assessed, reported and documented 
in the eCRF.  
6.3. Selection of  Investigators  
Surgeons who are qualified by training (board certified in abdominal and/or thoracic procedures in 
accordance with US A/European and hospital guidelines), education, and relevant experience 
appropriate to the use of the product and associated procedures will be considered for participation as 
investigators in this study. Investigators/sites must have adequate time and reso urces to conduct the 
study throughout the duration of the study and have access to an adequate number of eligible subjects. 
Investigators/sites must be able to comply with applicable Institutional Review Board (IRB)/Ethics 
Committee (EC) and regulatory req uirements. Investigator must not be debarred, disqualified, or 
working under sanctions in applicable regions. Qualifications are verified through valid Curriculum Vitae 
(CV)  and current licensing. Current license (US A only) and CVs will be maintained with study 
documentation.   
The Investigators and the associated clinical study staff will receive training on the management of the 
clinical study and the device according to the instructions for use (IFU).  
7. Product Description  
7.1. General   
The Signia™ stapler is a  reusable intelligent surgical stapler that provides push -button powered 
maneuverability and delivery of compatible stapling reloads. The Signia™ Stapling System is the 
combination of the Signia™ stapler and system accessories.  
The Signia™ stapler is compo sed of the Signia™ power handle, Signia™ power shell, and Signia™ 
adapters. The system accessories include a reusable insertion guide, a manual retraction tool, a single -
bay charger. The Signia™ stapler is compatible with En do GIA™ single ‑use reloads, Endo  GIA™ 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 21 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  
single‑use reloads with Tri ‑Staple ™ Technology, Tri ‑Staple ™ 2.0 single ‑use reloads, and Signia ™ 
Intelligent Loading Units with Tri ‑Staple ™ 2.0 single ‑use Reloads (see appendix A for Reloads to be 
assessed in this study) .  
7.1.1.  Signia™ Stapler  
A.  B. 
Figure 1:  The Signia™ Stapler including the Power 
Handle, Power Shell, Linear Adapter and Tri ‑Staple™ 
2.0 reload. (A) Side view, (B) Top view  
 
 
7.1.1.1.  Signia™ Power Handle  
The Signia™ power handle is a non -sterile reusable, battery -powered stapling handle that  includes 
microprocessors, electronics, motors, an OLED display screen, and a rechargeable lithium (Li) -ion 
battery.  
The Power Handle provides instrument intelligence (software) and contains a microprocessor, that 
controls supporting electronics, and motor  assemblies for rotation, articulation, jaw open/close and 
firing of compatible stapling reloads. The control of the reloads is provided by three motor assemblies in 
the handle, and then delivered to the attached Linear Adapter through multiple drive shaft s to deploy 
the compatible reloads.  
The “Intelligence Enabled” symbol is a trademarked symbol originated by Medtronic that is used in the 
branding of Signia™ Stapling products. It means that the product contains an ID -enabled IC chip. The 
chip will have th e ability to communicate with compatible Signia™ stapling products that also have an 
ID-enabled IC chip.  

Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 22 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  7.1.1.2.  Signia™ Power Shell  
The Signia™ power shell is a single ‑use, sterile shell that covers the non -sterile Signia ™ power handle to 
create an aseptic barrier, control interface, and universal adapter connector. It also provides a 
communications interface for Tri ‑Staple ™ 2.0 single ‑use reloads and Signia ™ Intelligent Loading Units 
with Tri‑Staple ™ 2.0 single -use Reloads  indicated for use with the Signia™ stapler.  
7.1.1.3.  Signia™ Linear Adapter (s) 
The Signia™ linear adapters  (short, standard and XL)  are non -sterile reusable instruments that attach to 
the stapling handle to enable functionality of compatible stapling reloads. Incl uded are motor mating 
connectors, electronic sensors, and communications interfaces for Tri ‑Staple ™ 2.0 single ‑use reloads 
and Signia ™ Intelligent Loading Units with Tri ‑Staple ™ 2.0 single -use Reloads  indicated for use with the 
Signia ™ stapler. It is provi ded non -sterile and must be cleaned and sterilized prior to each use as per the 
instructions for use.  
7.1.2.  Signia™ Accessories  
7.1.2.1.  Signia™ Reusable Insertion Guide  
The Signia™ reusable insertion guide is used to help maintain the sterility of the power shell during  
insertion of a non -sterile Signia™ power handle. It is provided non -sterile and must be cleaned and 
sterilized prior to each use as per the instructions for use.  
7.1.2.2.  Sign ia™ Manual Retraction Tool  
The Signia™ manual retraction tool is a reusable, handheld dev ice that can be used to operate the 
adapter controls in the event of a malfunction during operation. The tool can be used to complete a 
firing, retract the knife and open the jaws, and/or articulate a stapling reload. It is provided non -sterile 
and must be  cleaned and sterilized before use as per the instructions for use.  
7.1.2.3.  Signia™ Single -Bay Charger  
The Signia™ single -bay charger is designed for use as an accessory to the Signia™ stapler and is used for 
charging the Li -ion batteries within the power handle. The charger will monitor the state of charge of a 
charging battery and report its status using color LEDs.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 23 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  7.1.3.  Number of Devices to be Used  
The estimated quantity of each device to be used for this study is included below. Each site will receive 
approximately 2 Power Handles, Single -Bay Chargers and Power Cords along with sufficient Signia™ 
accessories and accommodate the number of anticipated procedures.  
 Device  Estimated number to be 
used in study.  
Signia ™ Power Handle  30 
Signia™ Power Shell  130 
Signia™  Linear Adapter (stnd, XL, short)  90 
Signia™ Reusable Insertion Guide  30 
Signia™ Manual Retraction Tool  30 
Signia™ Single -Bay Charger  30 
Signia™  Power Cord  30 
 
7.2. Manufacturer  
The Signia™ Stapling System is manufactured by Covidien LP. (Covidien LP is an  indirect wholly owned 
subsidiary of Medtronic plc.).  
7.3. Packaging  
The Signia™ Power Handle and Signia™ Single -Bay Charger are packaged as non -sterile reusable 
instruments.  
The Signia™ Power Shell is packaged as a single use, sterile shell for the Signia™ po wer handle.  
The Signia™ Linear Adapter, Signia™ Reusable Insertion Guide , and Signia™ Manual Retraction Tool  are 
packaged as non -sterile instruments and must be cleaned and sterilized prior to each use per IFU 
instructions.  
7.4. Intended Population  
The intended population for this study are subjects scheduled to undergo an indicated primary 
abdominal or thoracic procedure where the Signia™ Stapling System will be used per its instructions for 
use (IFU).  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 24 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  7.4.1.  Indications for Use  
The Signia™ stapler, when u sed with Endo GIA™ single -use reloads, Endo GIA™ single -use reloads with 
Tri‑Staple™ Technology,  Tri‑Staple ™ 2.0 single -use reloads  and Signia ™ Intelligent Loading Units with 
Tri‑Staple ™ 2.0 single -use Reloads , has applications in abdominal, gynecological,  pediatric, and thoracic 
surgery for resection, transection, and creation of anastomosis. It may be used for transection and 
resection of liver substance, hepatic vasculature, and biliary structures and for transection and resection 
of the pancreas.  
The Si gnia™ stapler, when used with Endo GIA™ curved tip single use reloads or Tri ‑Staple ™ 2.0 curved 
tip single -use reloads, can be used to blunt dissect or separate target tissue from other certain tissue.  
The Signia™ stapler, when used with Endo GIA™ single u se Radial Reloads with Tri ‑Staple ™ Technology, 
has applications in open or minimally invasive general abdominal, gynecologic, pediatric and thoracic 
surgery for resection and transection of tissue and creation of anastomosis, as well as application deep 
in the pelvis, i.e., low anterior resection. It may be used for transection and resection of liver substance, 
hepatic vasculature and biliary structures and for transection and resection of the pancreas.  
The Signia™ stapler, when used with Endo GIA™ single u se reinforced reloads with Tri ‑Staple ™ 
Technology preloaded with polyglycolic acid staple line reinforcement or Tri ‑Staple ™ 2.0 single use 
reinforced reloads preloaded with polyglycolic acid staple line  reinforcement, has applications in 
abdominal, gynecol ogic, pediatric and thoracic surgery for resection, transection of tissue and creation 
of anastomosis. It may be used for transection and resection of liver substance, hepatic vasculature and 
biliary structures, and for transection and resection of the pan creas.  
7.4.2.  Contraindications  
1. Refer to the Instructions for Use provided with the compatible Endo GIA™ single -use reloads, 
Endo GIA™ single -use reloads with Tri -Staple™ Technology, Tri -Staple™ 2.0 single -use reloads, 
and Signia™ Intelligent Loading Units with T ri-Staple™ 2.0 single -use Reloads  for specific 
indications, contraindications, warnings, and precautions.  
2. Tissue thickness should be carefully evaluated before firing any stapler. Refer to the Instructions 
for Use provided with the selected Endo GIA™ singl e-use reload, Endo GIA™ single -use reload 
with Tri -Staple™ Technology, Tri -Staple™ 2.0 single -use reload or Signia™ loading unit with 
Tri-Staple™ 2.0 single -use cartridge for the specific contraindications regarding compressed 
tissue thickness for the sele cted reload.  
3. Do not use the Signia™ stapler where adequacy of hemostasis cannot be verified visually after 
applications.  
4. Do not use any linear cutter on major vessels without making provisions for proximal and distal 
control.  
5. Do not use the instrument on i schemic or necrotic tissue.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 25 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  6. The Signia™ stapler should not be used on friable or delicate tissue where the closure of the 
device might be destructive.  
7. When using curved -tip reloads with the Signia™ stapler, do not use on tissue or structures that 
cannot fi t completely within the reload jaws proximal to the transitional angle of the curved tip.  
8. The Signia™ power shell is provided STERILE and is intended for use in a SINGLE procedure only. 
DISCARD AFTER USE. DO NOT RESTERILIZE.  
9. Endo GIA™ single -use reloads, E ndo GIA™ single -use reloads with Tri -Staple™ Technology, 
Tri-Staple™ 2.0 single -use reloads and Signia™ Intelligent Loading Units with Tri -Staple™ 2.0 
single -use Reloads  are provided STERILE and are intended for use in a SINGLE procedure only. 
DISCARD AFTE R USE. DO NOT RESTERILIZE.  
7.5. Equipment  
7.5.1.  Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 
Intelligent Reloads (single -use)  
The Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  place staggered 
rows of titanium staples and simultaneously divides the tissue so that three staggered rows of staples 
are placed on either side of the cut line. The size of the staples is determined by the selection of the 
cartridge.  
Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  are manufactured by 
Covidien LP. (Covidien LP is an indirect wholly owned subsidiary of Medtronic plc.).  See Section 18.1 
Appendix A for Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  to be 
assessed  in this study. Details for product use are described in the instructions for use that accompany 
each reload.  
7.6. Product Use  
Details for product use are described in the instru ctions for use and manuals for the Signia™ Stapling 
System.  
7.7. Product Training Requirements  
Each Investigator participating in the clinical study and the associated clinical study staff will receive 
training on the clinical protocol, as well as the Signia™ S tapling System. Investigators and study staff will 
be trained on device characteristics, shelf life and storage requirements, device use, and warnings, 
precautions, contraindications.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 26 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  7.8. Product Receipt and Tracking  
Signia™ Stapling Systems and accessories w ill be shipped to each site and each site will document the 
quantity and lot number of each component (See section 7.1) upon receipt. For each procedure the 
serial number of each component of the device being used will be recorded in the device accountabil ity 
log. 
7.9. Product Storage  
The Signia™ Stapling Systems will be labeled “Exclusively for Clinical Investigations” or similar language 
and should be stored in a secure (locked) area under the appropriate storage conditions (room 
temperature). Access should be  limited to designated study staff only.  
7.10.  Product Return  
It is the site’s responsibility to return the Signia™ Stapling System(s) and all associated Sign ia™ 
accessories to Medtronic within 30 days of the last patient enrolled at the site.  
7.11.  Product Accountabi lity  
Signia™ Stapling Systems will be provided to each site upon Sponsor collection and approval of all 
required regulatory documentation. The principal investigator or an authorized designee shall keep 
records documenting the receipt, use, return and dis posal of the investigational devices, which shall 
include:  
• the date of receipt,  
• identification of each investigational device (batch number/serial number or unique code),  
• the expiry date, if applicable,  
• the date or dates of use,  
• subject identification,  
• date on which the investigational device was returned/explanted from subject, if applicable, and  
• the date of return of unused, expired or malfunctioning investigational devices, if applicable.  
Device accountability will be tracked on a separate log  and kep t in the site binder.  It is the site’s 
responsibility to document the receipt (maintain shipping logs), disposition of the product (per subject 
use, including amount used, amount remaining, etc.), transfer (if applicable) and return of all unopened 
study d evices. The sponsor shall also keep records to document the physical location of all 
investigational devices from shipment of investigational devices to the investigation sites until return or 
disposal.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 27 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  8. Selection of Subjects  
8.1. Study Population  
A minimum of o ne-hundred twenty (12 7) subjects  ages 22 -80 inclusive at the time of the procedure 
enrolled in 2 study arms (abdominal or thoracic) at a pproximately 10  sites in US A and Europe  
(potentially in United Kingdom, Spain, Italy ). See Statistics (Section 13.2) for  additional details on sample 
size determination. It is estimated that the abdominal arm will comprise 5 3 subjects and the thoracic 
arms comprise 7 4 subjects.  
8.2. Subject Enrollment  
After being informed of the nature of the study, the subject will provide wri tten informed consent that 
has been approved by the sponsor and the appropriate IRB/EC of the respective clinical site (see section 
9.6 for additional details). A minimum  of 12 7 subjects will be enrolled in the study at a pproximately 10  
sites in the USA and Europe  (potentially in United Kingdom, Spain, Italy ) during  competitive enrollment 
not to exceed 15 subjects per site. Subjects’ participation in the study will last  approximately  30 days  
(+14  days)  post procedure. During the study , enrollment will conti nue until 127 subjects have enrolled.  
Once enrolled, patients will be included unless deemed necessary by the inclusion and exclusion criteria 
below.  
A subject is considered enrolled in the study when it is confirmed they meet inclusion and exclusion 
crite ria and ICF is signed and must be followed for the full 30 days if the procedure was begun or 
completed with the study device.  The time of enrollment to procedure should not exceed 30 days. If 
enrollment and/or ICF signature occur more than 30 days before  the procedure the subject is to be 
rescreened and reconsented. No study procedures will be performed until informed consent form has 
been completed.  
The procedure will be performed per the institution’s standard practice. Subjects will be considered for 
enrollment into the study if they meet specific screening inclusion/exclusion criteria. The criteria for 
enrollment must be followed explicitly.  
8.3. Inclusion Criteria  
1. Adults (male or female) between 22 and 80 years of age  inclusive  at the time of the procedure.  
2. The subject must be willing and able to participate in the study procedures and understand and 
sign the informed consent . 
3. The subject is scheduled to undergo an indicated primary abdominal or thoracic procedure for 
resection,  transection and creation of anastomosis per the IFU where the Signia™ Stapling 
System using Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  will 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 28 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  be used per its IFU. (See Section 18.1 Appendix A for Reloads  to be assessed  in this study)  
Additionally, if considered appropriate for the procedure only Medtronic buttresses can be used 
during the course of the study.   
a. Thoracic procedures may include, but are not limited to wedge resection and 
lobectomy, and may include video assisted thoracic surgery (VATS) or open procedures  
b. Abdominal procedures may include, but are not limited to, laparoscopic sleeve 
gastrectomy (LSG), laparoscopic Roux -en-Y gastric bypass (LRYGB)  
8.4. Exclusion Criteria  
1. Subjects undergoing cardiac and vascular p rocedures  
2. The procedure is an emergency procedure  
3. The procedure is a revision/reoperation of a primary operation  
4. Any female subject who is pregnant  
a. Females of child -bearing potential will be required to provide either a urine pregnancy 
test or serum pregna ncy test during Screening and confirmed on the day of operation 
(except for subjects who are surgically sterile or are post -menopausal for at least two 
years) (US A only) and per EU local requirements  
5. Any subject who is considered to be part of a vulnerable  population (e.g. prisoners or those 
without sufficient mental capacity)  
6. The subject is unable or unwilling to comply with the study requirements or follow -up schedule  
7. The subject has comorbidities which, in the clinical judgment of the Investigator, will not be 
appropriate for the study or the subject has an estimated life expectancy of less than 6 months  
8. The subject has been diagnosed with a bleeding disorder and/or is undergoing active and not 
reversed anticoagulant treatment.  
9. The subject is concurrently  enrolled in another investigational drug or device research study or 
has been enrolled in another study within 30 days of enrollment.  
Pre-existing/chronic conditions specific to Endo GIA™ Reloads with Tri -Staple™ Technology and Tri-
Staple™ 2.0 Cartridge contraindications as described in the IFU , respectively . 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 29 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  9. Study Procedures  
9.1. Schedule of Events  
9.1.1.  Study schematic  
Procedure/Assessment  Screening  
(Day -30 to 0)  Operative  
(Day 0)  Discharge 
Assessment  Follow -up 
Assessment  
(at 30  Days 
(+14  days )) Can be combined  
Informed Consent1  X    
Eligibility Criteria  X X   
Pregnancy check via u rine or serum 
pregnancy test  females of child bearing 
potentia l (US A only)  or per EU local 
requirements    X2 X2   
Demographic Data  X    
Vital Signs  X X   
BMI X    
Abbreviated Physical exam3 X X   
Medical and surgical history, including  
previous abdominal or thoracic surgical 
history  X    
American Society of Anesthesiologists (ASA) 
grade   X   
Operative date   X   
Operative start/stop times   X   
Type of procedure   X   
Anesthesia details   X   
Study device data4  X   
Use of feedback display  (if applicable)   X   
Concomitant medications5  X X X 
Procedure Related Adverse Events   X X X 
Adverse Device Effects (ADEs)   X X X 
Staple line assessment   X   
Device deficiencies/ malfunctions6  X   
Device Accountability   X   
Length of hospital stay    X  
Length of intensive care stay (if applicable)    X  
Surgical site and infection assessment by the 
Investigator according to the standard of 
care and site policy, ex. Positive wound 
culture    X X 
Readmission - related to primary procedure     X 
1. No study procedures will be performed until informed consent form has been completed. Subject should be re -consented if date of 
original consent is greater than 30 days.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 30 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Procedure/Assessment  Screening  
(Day -30 to 0)  Operative  
(Day 0)  Discharge 
Assessment  Follow -up 
Assessment  
(at 30  Days 
(+14  days )) Can be combined  
2. If Screening and Surgery occur on different days, these procedures should occur during Screening and be reconfirmed on the  day of 
surgery.  
3. Including height, weight, and examination of the heart, lung, and abdomen as applicable  
4. Including but not l imited to, staple size, number of firings, type of reload used, location of firings, lot number of devices used, 
malfunctions  
5. Only those related to relevant medical history or adverse events will be collected, e.g.: anticoagulants, blood pressure, antib iotics, pain 
medications  
6. Including but not limited to system set -up (insertion guide, power shell), OLED screen display, rotation, articulation, clamp/unclamp, 
firing, use of manual retraction tool   
9.2. Subject Screening  
A screening visit will be performed within 30 days up to the day of the scheduled procedure and may be 
combined with the surgery procedure visit . Subjects will be consented prior any procedures specific to 
the study are undertaken. The purpose and all aspe cts of the study will be explained to the subject. 
Subjects who agree to study participation must sign and personally date the sponsor and an IRB/EC -
approved informed consent form prior to participating in any study activities.  
Once informed consent has b een completed according to IRB/IEC requirements and eligibility is 
confirmed, the subject’s demographics and medical history will be assessed to include:  
• Eligibility Criteria  
• Subject demographics (e.g., sex, age, ethnicity and race if allowed per local re gulations)  
• Medical and surgical history (previous abdominal or thoracic surgical history, smoking history, 
anticoagulant therapies and prevalence of diabetes)  
• Vital signs (heart rate, temperature, respiratory rate, blood pressure)  
• Oxygen saturation levels  (pulse oximeter)  
• BMI 
• Abbreviated physical exam, including height, weight, and examination of the heart, lung, and 
abdomen  
• Serum or urine pregnancy test females of child bearing potential (USA only) or per EU local 
requirements  
9.3. Prior and Concomitant Medic ations  
Any prior or concomitant medication is allowed for this study at the discretion of the on -site physician. 
Prior or  concomitant medications related to relevant medical history or adverse events will be collected 
(e.g.: anticoagulants, blood pressure,  antibiotics, pain medications) . 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 31 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  9.4. Subject Consent  
Subjects (or legally authorized representatives) will be consented in the study prior to any procedures 
specific to the study are undertaken. Subjects (or legally authorized representatives) will be provided  
with a description of the device and procedure; risks, benefits, and alternative procedures; length of 
participation required; and information regarding injury and confidentiality. Subjects  (or legally 
authorized representatives) will be informed that the ir participation in this study is voluntary and they 
may refuse to participate or discontinue from the study at any time. Subjects (or legally authorized 
representatives) will be given the opportunity to ask the Investigator questions so that they are 
adeq uately informed about the research. The informed consent form must be personally signed and 
dated by subject (or le gally authorized representative ) and Investigator  or an authorized designee  
responsible for conducting the informed consent process  at time of consent. The informed consent 
process will be documented in the source records and a copy of the consent will be provided to the 
subject  (a signed copy where applicable) . If the subject (or le gally authorized representative ) completed 
consent f orm outside of 30 day s screening window, a new consent must be signed/dated prior to 
surgery.  
Medtronic will inform the investigators whenever information becomes available that may be relevant 
to the subject’s confirmed participation in the clinical study . The investigator or his/her authorized 
designee should inform the subject in a timely manner.  
Medtronic will revise the written Patient Information and Informed Consent Form whenever new 
information becomes available that may be relevant to the subject’ s confirmed participation in the 
clinical study. The revised information will be sent to the investigator for approval by the EC/IRB. After 
approval by the EC/IRB, a copy of this information must be provided to the participating subjects, and 
the informed consent process as described above needs to be repeated.  
9.5. Randomization and Treatment Assignment  
No randomization will occur during the course of the study.  
9.6. Medication Compliance  
Medication is not restricted during th e course of this  study and will be at the discretion of the on -site 
physician.  Concomitant medications relevant  to adverse events will be collected (e.g.: anticoagulants, 
blood pressure, antibiotics, pain medications) . 
9.7. Assessment of Efficacy  
Primary assessment will exami ne the i ncidence of  subjects reporting serious  adverse device effects up to 
and including 30 (+14) days  postoperative and device deficiencies/malfunctions affecting the intended 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 32 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  performance will be recorded in the eCRF  and used to assess the efficacy of the Signia™ stapling system.   
In addition, the following assessments will be collected:  
9.7.1.  Operative (Day 0)  
The Study Investigator should perform the surgical procedure according to the appropriate standard 
procedures and practices at his/her institution using the Signia™ Stapling System. Additionally, the 
following procedures and assessments will be performed:  
• Eligibility Criteria*  
• Vital signs (heart rate, temperature, respiratory rate, blood pressure, pulse, oxygen satur ation 
levels)*  
• Abbreviated physical exam, including height, weight, and examination of the heart, lung, and 
abdomen*  
• American Society of Anesthesiologists (ASA) grade (See Appendix B, Section 18.2)  
• Serum or urine pregnancy test females of child bearing pot ential (USA only) or per EU local 
requirements *  
* Assessments only need to be repeated if Screening/Operative Visit occur on different days  
• Operative date  
• Operative start (skin incision) and stop times (skin closure)  
• Type of procedure  
• General anesthesia i nformation (type, start and stop times)  
• Study device data (i.e.,  type of reload used, staple size, lot number of devices used, number of 
firings, location of firings)  
• Use of Signia feedback display  (if applicable)  
• Relevant concomitant medications (only tho se related to relevant medical history or adverse 
events will be collected e.g .: anticoagulants, blood pressure, antibiotics, pain medications)  
• Procedure related adverse events  
• Adverse device effects (ADEs) (ADEs, as defined by ISO14155 -2011, see section 11.1.3 for 
additional details)  
• Staple line assessment  
• Device deficiencies/malfunctions affecting intended performance to include but not limited to;  
o System set -up (insertion guide, power shell)  
o Organic light emitting diode (OLED) screen display  
o Rotation  
o Articulation  
o Clamp/UnClamp  
o Firing  
o Use of manual retraction tool  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 33 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  o User errors  
o Unintended cutting  
o Insufficient staple deployment  
o Inability to complete the firing sequence  
o Stapling without cutting  
• Device accountability  
9.7.2.  Discharge Assessment  
On the day of discha rge the following assessments will be made:  
• Procedure related adverse events  
• Adverse device effects (e.g. air leak, anastomotic leak, staple line bleeding, peritonitis, sepsis, 
intracavitary infection, intervention or reoperation)  
• Length of hospital stay  
• Length of intensive care unit stay (if applicable)  
• Surgical site and infection assessment by the Investigator according to the standard of care and 
site policy, ex. Positive wound culture  
• Relevant concomitant medications (only those related to relevant me dical history or adverse 
events will be collected e.g .: anticoagulants, blood pressure, antibiotics, pain medications)  
9.7.3.  Follow -up Assessments (Day 30 +14 days))  
On post -operative day 30, assessments will take place by delegated study personnel. Assessments will 
include:  
• Readmission related to primary procedure  
• Procedure related adverse events  
• Adverse device effects (ADEs)  
• Surgical site and infection assessment by the Investigator according to their the standard of care 
and site policy, ex. Positive wound cu lture  
• Relevant concomitant medications (only those related to relevant medical history or adverse 
events will be collected e.g .: anticoagulants, blood pressure, antibiotics, pain medications)  
After the study has been completed no further study specific med ical care will be provided and subjects 
will receive standard of care.   
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 34 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  9.8. Assessment of Safety  
Safety will be assessed by monitoring the occurrence of adverse events (AEs), serious adverse events 
(SAEs), death, adverse device effects (ADE), unanticipated se rious adverse device effects (USADE), 
device deficiency/malfunction, and/or device misuse. Assessments will take place during the procedure 
through post -operative day 30  (+14 days)  and will be recorded in the eCRF.  
9.9. Recording Data  
This study will utilize a n electronic database and eCRF . All data requested on the eCRF are required. 
Study visits or measurements not collected and/or recorded will be considered deviations unless 
otherwise specified. The Principal Investigator or authorized designee(s) must ensu re the accuracy and 
completeness of the recorded data and then provide his/her electronic signature on the eCRFs. The 
Investigator’s electronic signature for specific eCRFs will be documented in compliance with local 
regulations and compliance with the pro tocol. Changes to data previously submitted to the sponsor will 
require a new electronic signature by the Investigator to acknowledge/approve the changes . 
9.10.  Deviation Handling  
The Investigator is not allowed to deviate from the CIP, except under emergency circumstances to 
protect the rights, safety and well -being of human subjects, otherwise no changes to the protocol will be 
permitted without the written approval from Medtronic , the IRB/EC and Competent Authority. The 
investigator must notify Medtronic and the reviewing IRB/EC of any deviation from the Investigational 
Plan. The deviation will be recorded in the eCRF and such notice must be given as soon as possible, but 
in no ev ent later than 5 working days after the emergency has occurred. Except in such an emergency, 
prior written approval by Medtronic is required for changes in or deviations from the Plan. If these 
changes or deviations affect the scientific soundness of the P lan or the rights, safety, or welfare of 
human subjects the IRB/EC will also be notified. All other deviations will be reported per the site’s 
IRB/EC deviation policy. Should any deviations from the Investigational Plan occur, these will be 
reviewed by Med tronic for their clinical significance and compliance to the protocol. Repetitive or 
serious investigator compliance issues may result in the need to initiate a corrective action plan, and in 
some cases , freeze enrolment or ultimately terminate the Investi gator’s participation in the clinical 
study . 
If it is discovered that an investigator is not complying with the signed Investigator Agreement, the 
investigational plan, applicable laws, or any conditions of approval imposed by the reviewing IRB/EC, the 
mon itor will report to the Sponsor and take such steps necessary to promptly secure compliance. If 
compliance cannot be secured, device shipments to the investigator may be discontinued and the 
investigator’s participation in the investigation terminated. The  monitor shall also require such an 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 35 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  investigator to dispose of or return the device, unless this action would jeopardize the rights, safety, or 
welfare of a subject.  
9.11.  Subject Withdrawal or Discontinuation  
9.11.1.  Enrolled  
A subject is considered enrolled in the study when it is confirmed they meet inclusion and exclusion 
criteria and ICF is signed and dated by subject and the Investigator and must be followed for the full 30 
days if the procedure was begun or completed with  the study device. Enrollment can take place 30 days 
before procedure and subjects will be followed for 30 (+14) days postoperative . If enrollment occurs 
greater than 30 days prior to procedure the subject will require to be reconsented.  
9.11.2.  Screen Failure  
Subjects who provide study consent, but then are determined to be ineligible prior to the procedure 
with the study device will be considered a screen failure and will not require additional study follow -up 
visits. The reason for the screening failure will be  clearly delineated on the applicable eCRFs.  
9.11.3.  Discontinuation  
Subjects who provide study consent, and are deemed eligible, but for which do not undergo the 
procedure with the study device will be considered “discontinued” and will be followed until dischar ge. 
These subjects will only contribute AE data intra -operatively until discharge (no additional follow -
up). Follow up of subjects withdrawn or discontinued will be determined by investigator. Safety and 
device deficiency data will not be collected from th e discontinued population.  
9.11.4.  Withdrawal  
The reason for study exit, including screen failure, will be documented on the applicable electronic case 
report form (eCRF). In the event the subject withdraws consent during the study, the date of withdrawal 
will be  documented. If the Study Investigator voluntarily removes a subject from further study 
participation, supporting documentation must be in place for the rationale and date of removal. Follow 
up of subjects withdrawn or discontinued will be determined by in vestigator.  
9.11.5.  Lost to Follow -up 
Every attempt will be made to contact subjects that are noncompliant with study procedures. Subjects 
will be considered lost to follow -up once the following steps have been taken:  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 36 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • Two phone calls should be made to the subject . Each attempt should be clearly documented in 
the source documents and the response or lack thereof should be captured.  
• If there is no response to the phone calls, then an official, certified letter should be written to 
the subject. A copy of the letter and return or delivery receipts should be retained in the 
subject’s source document.  
• When all due diligence attempts to contact have been made, after a period of two (2) weeks, 
the subject will be considered Lost to Follow -up. The Sponsor must be notified and the End of 
Study (EOS) form must be completed.  
10. Risks and Benefits  
10.1.  Potential Risks  
Surgeons participating in this study are experienced with the known risks related to standard of care for 
abdominal and thoracic surgeries. Risks associated with participation in the clinical investigation and  use 
of the Signia™ Stapling System with approved  reloads  in abdominal and thoracic procedures include, but 
are not necessarily limited to: adhesions, air leak, anastomotic leakage, atelectasis, bile leak, biliary 
fistula, bleeding, bronchopneumonia, cardiac complications, death, gastric leak, heart failure, 
hem atoma, infection, inflammation, intra -abdominal fluid collection, liver failure, pleural effusion, 
pneumothorax, pulmonary embolism, stricture, ulceration, and wound dehiscence.  
The instructions for use (IFU) will guide surgeons on proper use of the device . Surgeons and site staff will 
undergo training on the device prior to participation in the study.  
Animal studies to evaluate the potential for AEs on reproductive ability and effects on the embryo/fetus 
have not been conducted. As with any device, there is always a risk of a rare or previously unknown side 
effect developing from the treatment or use of the device.  
The risk analysis report s are based on the operation of Signia™ Stapling System by trained personnel. 
According to the Risk Analysis Chart, the re were no unacceptable residual risks in the Zone 3 category 
(red) proceeding mitigation activities. The following are all residual risks that exist in a Zone 2 category 
(yellow) proceeding mitigation activities  for the Signia™ Stapling System . These risk s do not directly 
result from design or manufacturing failures, so the risk has been reduced as far as possible with 
appropriate mitigation controls in place:  
• Non -sterile product  
• EtO Residuals  
• Exposure to Bio -Hazard  
• Difficult Insertion through Port or Org an 
• Non -functional Staple Closure (identified Intra - or Post - Operatively)  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 37 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • Unintentional Firing  
• Device Cuts without Stapling  
• Reload Locks on Tissue  
• Uncontrolled Rotation or Articulation  
• Loss of Tissue Sensing Speed Control  
• Reload De -articulates when Clamped  on Tissue  
The overall residual risk after design risk mitigation strategies and/or design control was deemed 
acceptable in the Risk Management Report s for the Signia™ Stapling System.  
10.2.  Potential Benefits  
The information obtained from this study will be us ed to confirm the safety and performance of the 
Signia™ Stapling System. This information may or may not lead to findings that could result in a 
reduction of complications for future patients.  
10.3.  Risk-Benefit Rationale  
A positive risk/benefit ratio has been demonstrated with the Signia™ Stapling System with appropriate 
reloads  as evidenced by preclinical and biocompatibility testing.  
The Signia™ Stapling System is a class II FDA 510K cleared product, and a MDD class IIa and class I CE -
marked product. Consequently, the Signia™ Stapling System presents a favorable risk/benefit ratio to 
the subject. The instructions for use (IFU) in addition to surgeon training, will instruct surgeons on 
proper use of the device to mitigate risk. There are currently no kn own interactions between the 
Signia™ Stapling System and concurrent medical interventions.  
11. Adverse Event s and Device Deficiencies  
Adverse event (AE) definitions used in this study are based on ISO 14155:2011 (Clinical Investigation of 
Medical Devices for Human Subjects -- Good Clinical Practice).  
Foreseeable adverse events and ant icipated adverse device effects can be found in the i nstructions for 
use. The instructions for use (IFU) in addition to surgeon training, will instruct surgeons on proper use of 
the device to mitigate these risks.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 38 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  11.1.  Definitions/Classifications  
11.1.1.  Adverse Event (AE)  
In alignment with ISO 14155:2011 (Section 3.2),  an Adverse Event is any untoward medical occurrence, 
unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in 
subjects, users or other persons, whether or not related to the investigational medical device.  
This definition includes events related to the study device and the procedures involved. For users or 
other persons, this definition is restricted to events related to study devices.  
For study purposes, the following occurrences are considered to be expected o bservations following 
surgical procedures (primarily associated with anesthesia) and will not be considered reportable AEs, as 
long as the event is not associated with significant sequelae, does not prolong hospitalization, and 
responds to standard medical  therapy:  
• Postoperative transient nausea determined to be procedure related within the first 24 
postoperative hours.  
• Postoperative transient emesis determined to be procedure related within the first 24 
postoperative hours.  
• Postoperative constipation, determined to be procedure and/or medication related for the 
duration of medication administration for management of pain.  
• Postop pain that the Investigator considers common and within normal limits for the procedure 
and is well -managed with medication.  
For study purposes procedure related adverse events will be collected and documented at the time of 
the procedure and up to and including  the 30 day (+14 days) post -operative follow up  visit. 
11.1.2.  Serious Adverse Events (SAE)  
In alignment with ISO 14155:2011 (Section 3.37), a serious adverse event (SAE) is any AE that has:  
• led to death,  
• led to serious deterioration in the health of the subject that either resulted in  
o a life -threatening illness or injury, or  
o a permanent impairment of a body structure or a body function, or  
o in-patient or prolonged hospitalization, or  
o medical or surgical intervention to prevent life threatening illness or injury or 
permanent impairment to a body structure or a body function, or  
• led to fetal distress, fetal death, or a congenital a bnormality or birth defect.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 39 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  NOTE: Planned hospitalization for a pre -existing condition or a procedure required by the clinical 
investigational plan, without serious deterioration in health, is not considered an SAE.  
SAEs will be collected and documented at  procedure and up to and including  the 30 day  (+14 day) post -
operative  follow -up visit. 
11.1.3.  Adverse Device Effect (ADE)  
In alignment with ISO 14155:2011 (Section 3.1), an Adverse Device Effect is an adverse event related to 
the use of an investigational medica l device.  
This definition includes  adverse events resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any deficiency/ malfunction  of the 
investigational medical device.  
This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device.  
Adverse Device Effects will be reported by the Investigator(s). If escalation is required (due to the 
potential need for reporting) ADEs will be r eviewed by Medtronic Medical Affairs. Both confirmed and 
possible adverse device effect events will be included in the study report.  
Examples of adverse device effects  include but are not limited to: leaking or bleeding due to non -
functional staple closure , damage to surrounding tissue due to unintentional firing, unintentional tissue 
loss due to reload locks on tissue  
ADEs will be collected and documented at procedure and up to and including  the 30-day follow -up visit. 
11.1.4.  Serious Adverse Device Effect (SADE)  
In alignment with ISO 14155:2011 (Section 3.36), a Serious Adverse Device Effect is an adverse device 
effect that has resulted in any of the consequences characteristic of a serious adverse event.  
SADEs will be collected and documented at procedure and up  to and including  the 30-day follow -up 
visit. 
11.1.5.  Unanticipated Serious Adverse Device Effect (USADE)  
In alignment with ISO 14155:2011 (Section 3.42), an Unanticipated Serious Adverse Device Effect is a 
serious adverse device effect which by its nature, incide nce, severity, or outcome has not been 
identified in the current version of the risk analysis report.  
NOTE: Anticipated serious adverse device effect (ASADE) is an effect which by its nature, incidence, 
severity or outcome has been identified in the risk analysis report.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 40 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  USADEs will be collected and documented at procedure and up to and including  the 30-day follow -up 
visit. 
11.1.6.  Device Deficiencies  
In alignment with ISO14155:2011 (Section 3.15), a Device deficiency is an inadequacy of a medical 
device -related to its identity, quality, durability, reliability, safety or performance; such as malfunction, 
misuse or use error and inadequate labeling.  
All Signia™ Stapling System device deficiencies/malfunctions will be documented on the Device 
Deficiency/Malfunction  eCRF.  
In the event of a device deficiency the device should be returned to Covidien for analysis, if possible. 
Instructions for returning the study device will be provided. Device deficiencies should also be 
documented in the subject’s medical record.  
Device deficiencies are NOT to be reported as AEs.  
However, if there is an AE that results from a device deficiency, that specific event would be recorded on 
the appropriate eCRF.  
11.1.7.  Adverse Event Severity Classification  
Severity will be  defined according to th e following criteria: 
Mild Awareness of event, but easily tolerated 
Moderate Discomfort enough to cause some interference with activities of 
daily living (ADL) 
Severe Incapacitating, with an inability to perform ADL 
Death  Death related to AE  
An AE can be classified as severe and not d eemed an SAE. Simil arly, an SAE is not autom atically severe 
in nature. 
11.1.8.  Adverse Event Relationship Classification  
Causality assessments define the relationship between the use of the medical device (including the 
medical -surgical procedure) and the occurrence of each adverse event, according to MEDDEV 
(Guidelines on Medical Devices, Clinical Investigations: Serious Adverse Event Reporting). The presence 
of confounding factors, such as concomitant medication/treatme nt, the natural history of the underlying 
disease, other concurrent illness or risk factors shall also be considered.  
Each AE will be classified according to five different levels of causality. The sponsor and the investigators 
will use the following defin itions to assess the relationship of the serious adverse event to the 
investigational medical device or procedures:  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 41 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Not related : relationship to the device or procedures can be excluded when:  
1. the event is not a known side effect of the product category the  device belongs to or of similar 
devices and procedures  
2. the event has no temporal relationship with the use of the device or the procedures;  
3. the serious event does not follow a known response pattern to the medical device (if the 
response pattern is previo usly known) and is biologically implausible;  
4. the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasible – and reintroduction of its use (or increase of the 
level of activation/exposure), do not impact on the serious event;  
5. the event involves a body -site or an organ not expected to be affected by the device or 
procedure;  
6. the serious event can be attributed to another cause (e.g. an underlying or concurrent illness/ 
clinical condition, an effect of another device, drug, treatment or other risk factors);  
7. the event does not depend on a false result given by the device used for diagnosis, when 
applicable;  
8. harms to the subject are not clearly due to use error;  
9. In order to es tablish the non -relatedness, not all the criteria listed above might be met at the 
same time, depending on the type of device/procedures and the serious event.  
 
Unlikely : the relationship with the use of the device seems not relevant and/or the event can b e 
reasonably explained by another cause, but additional information may be obtained.  
Possible : the relationship with the use of the device is weak but cannot be ruled out completely. 
Alternative causes are also possible (e.g. an underlying or concurrent il lness/ clinical condition or/and an 
effect of another device, drug or treatment). Cases were relatedness cannot be assessed or no 
information has been obtained should also be classified as possible.  
Probable : the relationship with the use of the device see ms relevant and/or the event cannot reasonably 
be explained by another cause, but additional information may be obtained.  
Causal relationship : the serious event is associated with the device or with procedures beyond 
reasonable doubt when:  
1. the event is a k nown side effect of the product category the device belongs to or of similar 
devices and procedures;  
2. the event has a temporal relationship with device use/application or procedures;  
3. the event involves a body -site or organ that  
a. the device or procedures are applied to;  
b. the device or procedures have an effect on;  
4. the serious event follows a known response pattern to the medical device (if the response 
pattern is previously known);  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 42 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  5. the discontinuation of medical device application (or reduction of the level of 
activation/exposure) and reintroduction of its use (or increase of the level of 
activation/exposure), impact on the serious event (when clinically feasible);  
6. other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an 
effect of another device, drug or treatment) have been adequately ruled out;  
7. harm to the subject is due to error in use;  
8. the event depends on a false result given by the device used for diagnosis, when applicable;  
9. In order to establish the relatedness, not all  the criteria listed above might be met at the same 
time, depending on the type of device/procedures and the serious event.  
 
The Sponsor and the Investigators will distinguish between the serious adverse events related to the 
device and those related to th e procedures (any procedure specific to the clinical investigation). An 
adverse event can be related both to procedures and the device. Complications of procedures are 
considered not related if the said procedures would have been applied to the subjects al so in the 
absence of device use/application.  
In some particular cases the event may be not adequately assessed because information is insufficient 
or contradictory and/or the data cannot be verified or supplemented. The sponsor and the Investigators 
will m ake the maximum effort to define and categorize the event and avoid these situations. Where the 
sponsor remains uncertain about classifying the serious event, it should not exclude the relatedness and 
classify the event as “possible”.  
Particular attention  shall be given to the causality evaluation of unanticipated serious adverse (device) 
events. The occurrence of unanticipated events related to the use of the device (USADE) could suggest 
that the clinical investigation places subjects at increased risk of  harm than was to be expected 
beforehand  
11.1.9.  Adverse Event Outcome Classification  
Outcome  of the event will be  defined according  to the following: 
• Fatal : This event is d etermined to be  the cause of death.  
• Not Recovering/Not Resolved : The event has retained p athological conditions resulting  from the  
prior disease or injury. 
• Recovered/Re solved: The event has fully resolved at the  end of the study. 
• Recovering/Resolving : The event is on going at the  end of  the study. 
• Unknown : The event has been unclassified at the end of the study.  
11.2.  Reporting of Adverse Events  
The following events are generally considered reportable during the course of this study and should be 
reported to the sponsor:  
• any device related AE, SADE, SAE, or USADE  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 43 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  • any Device Deficiency/Malfunction that might have led to a SADE if  
o suitable action had not been taken or  
o intervention had not been made or  
o if circumstances had been less fortunate  
• new findings/updates in relation to already reported events.  
Events will be reviewed by the sponsor to determine any reporting obligations to National Competent 
Authorities and IRBs/ECs.  
The following table captures the reporting requirements for this study. Local and regional regulatory 
requirements shall be follo wed in addition to study requirements.  
 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 44 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Type of Event  Timeframe  Submit to  
Any Death  As soon  as practicable  but no more than 
10 work days after the day  that  you 
become aware of information from any 
source, that   reasonably  suggests that a 
device has or may have caused or 
contributed to   the death  of a patient  of 
your  facility  Sponsor / Device Manufacturer  and Local (IRB/ 
EC) and regional regulators (FDA)  
 
UADE  As soon  as possible,  but in no event 
later than 10 working days after    the 
investigator first learns of the effect.  
 Sponsor  / Device Manufacturer  and any local/ 
regionally required regulators  
 
All Serious 
Events including 
SAEs, USADEs, 
Serious Injuries 
or Significant 
Safety Issues  Within 24 hours, but no later than 10 
work days (and/or per local 
requirements) after the   day that 
investigator becomes aware of 
information, from any source,  that  
reasonably suggests that a device has or 
may have caused  or contributed to a 
serious injury  to a patient of your 
facility.  
 Sponsor / Device Manufacturer  and as per local 
reporting requirements.  
 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 45 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  Assessment of the occurrence of an AE will be based on changes in the subject’s abbreviated physical 
examination, laboratory results and/or signs and symptoms. Adverse events will be monitored until a 
subject completes the study unless the Investigator det ermines the event is related to the device, in 
which case they will be monitored until resolution if possible. Medical care will be provided, as defined 
in the informed consent, for any AE related to study participation. Adverse events will be collected on  an 
AE eCRF and applicable source documentation. To the extent possible, the event to be recorded and 
reported is the event diagnosis as opposed to event symptoms (e.g., fever, chills, nausea and vomiting in 
the presence of a clinically diagnosed infection  is to be reported as infection only). For the purposes of 
this protocol, only those AEs occurring after enrollment will be recorded.  
The following should not be considered an AE:  
• A condition requiring a preplanned procedure unless the condition worsened since screening  
• A preexisting condition found as a result of screening, unless the condition has worsened since 
enrollment.  
All responses to the above events that require treatment beyond the institution’s standard procedures 
will be reported as AEs.  
All d evice and procedure related AEs observed during the course of this study (up to and including  the 
30day follow up  visit), regardless of severity or relationship to the device will be recorded on the 
appropriate eCRF.  
11.3.  Study Contact Information  
Questions reg arding safety or medical procedures should be directed to Medtronic MITG Medical 
Affairs. All other questions including emergency contact for reporting serious adverse events and serious 
adverse device effects  should be directed to Medtronic MITG Surgical Innovations, Clinical Research.  
Medical Affairs  
Christine Mauro, MD, MMSc  
Director, Medical Affairs  
Medtronic  
MITG Surgical Innovations  
555 Long Wharf Drive  
New Haven, CT 06511 USA  
Phone: 203 -361-8276  
Christine.Mauro@medtronic.com  Matthew Savary, MD  
Director, Medical Affairs  
Medtronic  
MITG  
5920 Longbow Drive  
Boulder, CO  80301  USA 
Phone:  203.530.1395  
Matthew. Savary@medtronic.com  
 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 46 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  12. Data Review Committees  
12.1.  Safety Committee  
An internal Medtronic Safety Team will review the overall rates of protocol defined adverse events (SAEs 
and events related to the primary and secondary  endpoints) on a quarterly basis. The committee will 
have the ability to make recommendations and reques t further information as required.  
12.2.  Independent Medical Monitor  
Medtronic will utilize an Independent Medical Monitor to provide an independent adjudication of pre -
specified adverse events in support of protocol defined endpoint data. The Independent Medica l 
Monitor will be a qualified, board -certified surgeon that is not affiliated with an investigative center. The 
Independent Medical Monitor will contribute to safety aspects of the clinical study and will conduct the 
study Safety Review Meetings and will r eview the key events and data in the event of Serious Adverse 
Events.  
The Independent Medical Monitor will be blinded to the investigational sites.  
12.3.  Steering Committee  
The Steering Committee will consist of Investigators participating in this study, as well  as appropriate 
members of Medtronic Clinical and Medical Affairs. The role of the Steering Committee is to make 
recommendations on the design and conduct of the study, the analysis of data, and the communication 
of results in alignment with the Medtronic Publication and Authorship Policy. The Steering Committee 
will also review aggregate adverse event data on an as needed basis, as described in the Steering 
Committee Charter.  
13. Statistical Design and Methods  
13.1.  Statistical Test Methods  
Continuous variables will  be summarized using counts, means, standard deviations, medians, minimum 
and maximum. Categorical variables will be summarized using frequencies and percentages. Changes to 
the planned statistical analysis as defined in the protocol will be documented in the statistical analysis 
plan and clinical study report.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 47 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  13.2.  Sample Size Determination  
Sample size was determined based on the primary endpoint ( incidence of subjects report ing serious  
adverse device effects (ADEs) up to and including 30 days including intra - and post -operative leaks ), but 
considering an acceptable probability (≥ 80%) to observe at least one adverse device effect  (ADE)  within 
30 days, in each arm (abdominal or thoracic indication).  
A previous Medtronic study (ClinicalTrials.gov ID   [STUDY_ID_REMOVED]) conducted on N=100 subjects and 
evaluating an equivalent device (Endo GIA™ Reinforced Reload with Tri -Staple™ Technology) in the same 
indications and with a similar design and follow -up reported the following adverse device effects rates 
(des cribed as “device related adverse events” with the study protocol and final report):  
 
  Abdominal  Thoracic  
Adverse device effect incidence  3.3%  2.5% 
 
Because of the expected low adverse device effect incidence rate (<5%) in the Abdominal or Thoracic 
procedures, as described above, a Poisson distribution is applied to estimate the probability of observing 
AE event(s).  
In the Abdominal indication, for an anticipated sample size of 5 3 subjects using an adverse device effect 
rate of 3.3%, and including a 5% attrition rate within 30 days , we obtain a probability of 81% to observe 
at least 1 adverse device effect.  
In the Thoracic indication, for an anticipated sample size of 7 4 subjects using an adverse device effect 
rate of 2.5%, and including a 5% attritio n rate within 30 days , we obtain a probability of 83% to observe 
at least 1 adverse device effect.  
For the overall population (in both indications), with a sample size of 127 subjects and considering an 
averaged adverse device effect rate of 2.9%, and incl uding a 5% attrition rate within 30 days , we obtain 
a probability of 97% to observe at least 1 adverse device effect, and a probability of 86% to observe at 
least 2 adverse device effects.  
In any scenario, we will have ≥ 80% probability to observe at least  1 adverse device effect in each arm.  
13.3.  Analysis Population  
The full analysis set  (FAS)  will consist of all enrolled and treated subjects  (using Signia™ ). For this study 
the full analysis set corresp onds to the safety population. FAS will serve as the primary analysis population 
for safety and performance analyses, as well as for demographics and baseline data analysis.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 48 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  The per protocol (PP) population will consist of all subjects from the FAS  population who do not have a 
major protocol violation. Analy ses on the PP population  will provide supporting evidence to the primary 
results  (obtained on FAS) .  
13.4.  Statistical Analysis Endpoints  
13.4.1.  Primary Endpoint  
The primary endpoint is the incidence of subjects reporting serious adverse device effects up to and 
includ ing 30 days  (+14days)  post -procedure which utilizes the Signia™ Stapling System . It will be 
summarized using descriptive statistics.  
A two -sided 95% confidence interval will also be calculated.  The acceptance criteria for this endpoint is 
an upper limit of the 95% CI below 20%.  
The analysis will be performed in abdominal group and in thoracic group, and in the combined groups.  
13.4.2.  Secondary Endpoint  
The incidence of secondary  outcome measures will be summarized using descriptive statistics:  
• counts and percent ages for categorical data  
• mean, standard deviation, median, minimum and maximum for quantitative data.  
13.5.  Handling of Missing Data  
No data imputation will be performed for missing data unless otherwise noted in statistical analysis 
plan. All practical monitor ing and follow -up steps will be taken to ensure complete and accurate data 
collection .  
Sample size has been determined including an attrition rate of 5% within 30 days for primary endpoint 
analysis.  
13.6.  Interim Analysis  
A preliminary analysis will be conduct ed in the study when 64 enrolled subjects complete the 30 day 
follow up visit.  The objective is to confirm early safety of the product.  This interim analysis data review 
is driven by regional  needs, to support a regulatory submission.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 49 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  14. Ethics  
14.1.  Statement(s)  of Compliance  
This clinical investigation will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, Good Clinical Practice guidelines, ISO14155:2011, and any regional 
or national regulations such as FDA regulations (US A), as appropriate. All principles of the Declaration of 
Helsinki have been implemented in this clinical study by means of the subject informed consent process, 
IRB/EC approval, clinical study training, clinical study registration, pu blication policy.  
The clinical investigation will not begin until all necessary approvals/favorable opinions are obtained 
from the appropriate IRB/EC or regulatory authority, as appropriate. Should an IRB/EC or regulatory 
authority impose any additional r equirements, they will be followed.  
Information regarding the study and study data will be made available via publication on clintrials.gov. 
Additionally, the results of this study will be offered for publication at the conclusion of the study, if 
partici pating investigators believe the data warrants publication in an appropriate journal.  
15. Study Administration  
15.1.  Monitoring  
Site visits will be conducted by an authorized Medtronic representative to qualify potential sites, 
conduct site initiation, ensure compl iance, assess informed consent process, conduct interim monitoring 
visits to monitor study data, subjects’ medical records, eCRFs, device accountability, device use and 
storage, IRB/EC submissions, regulatory binder in accordance with current protocol, GCP s and the 
respective local and national regulations and guidelines (as applicable) as well as close -out site activities. 
The Study Investigator and the investigating site will permit authorized clinical research personnel from 
Medtronic or contracted by Me dtronic to review completed eCRFs, IRB/EC decisions, and Investigator 
and clinical site records at regular intervals throughout the study as well as permit study -related 
monitoring, audits, EC/IRB review, and regulatory inspection(s) by providing direct ac cess to source 
data/documents.  Additionally, subject charts and clinical records will be requested and reviewed so that 
protocol adherence and source documentation can be verified. In instances where data protection 
regulations prohibit the direct examina tion of hospital records by the study Sponsor or designee(s), the 
Investigator will cooperate in a method of source data verification with the Sponsor  detailed in the 
monitoring plan . Monitoring may be performed with in person visits or remotely, when appl icable.   
To ensure the rights, safety, and welfare of study subjects are being maintained, the monitor will 
maintain assurance that all study staff are trained on the study protocol and use of the study devices. If 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 50 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  the monitor discovers that an investigato r is not complying with the signed Investigator Agreement, the 
investigational plan, applicable laws, or any conditions of approval imposed by the reviewing IRB/EC, the 
monitor will report to the Sponsor and take such steps necessary to promptly secure com pliance. If 
compliance cannot be secured, device shipments to the investigator may be discontinued and the 
investigator’s participation in the investigation terminated. The monitor shall also require such an 
investigator to dispose of or return the device,  unless this action would jeopardize the rights, safety, or 
welfare of a subject.  
15.2.  Data Management  
Data review will be performed to identify possible data discrepancies. Manual and/or automatic queries 
will be created in the remote data capture (RDC) system  and will be issued to the site for appropriate 
response. The site staff will be responsible for resolving all queries in the database within 60 days. 
Medications will be coded under the WHO dictionary while Medical History, Surgical History and/or 
Adverse  Events will be coded in Medical Dictionary for Regulatory Activities (MedDRA). Any data to be 
recorded directly on the CRFs and to be considered source data  
This study will be using a US A FDA 21 CFR Part 11 compliant electronic data capture system. All sy stem 
level validation documentation is retained within the Information Systems group.  
15.3.  Direct Access to Source Data/Documents  
Investigator(s)/institution(s) will permit study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s), and pro vide direct access to source data/documents as per local policies and regulations.  
15.4.  Confidentiality  
All records identifying the subject will be kept confidential and, to the extent permitted by the 
applicable laws and/or regulations.  
Subject names will be k ept confidential. Only the site id number and subject number will be recorded in 
the eCRF, and if the subject name appears on any other document, it must be redacted. Study findings 
stored on a computer will be stored in accordance with local data protecti on laws. The subjects will be 
informed in writing that representatives of the sponsor, IRBs/ECs, or Regulatory Authorities may inspect 
their medical records to verify the information collected, and that all personal information made 
available for inspectio n will be handled in strictest confidence and in accordance with local data 
protection laws. Subjects will also be informed that information regarding the study that does not 
include subject identifiers will be posted on the US A FDA required study registry , clinicaltrials.gov and/or 
other regional registries/local public database if required.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 51 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  If the results of the study are published, the subject’s identity will remain confidential.  
The investigator will maintain a subject master list to enable subjects’ r ecords to be identified.  
15.5.  Liability  
Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insuran ce statement/certificate will be provided to the IRB/EC.  
15.6.  CIP Amendments  
A CIP/Protocol amendment will be prepared when there are revisions that are significant changes or 
corrections, or modifications that impact subject safety, ethical conduct, data inte grity or study design. 
CIP/Protocol amendments must undergo review and approval by the sponsor, IRB/EC and any 
appropriate regulatory authority, and will be logged in the document version history (Section 18). 
IRB/EC approval, regulatory authority approval , site training and a new Acknowledgement form will be 
signed and returned before any new procedures take place.  
15.7.  Record Retention  
The investigator and the sponsor will maintain the records of the study including all pertinent 
correspondence, the study prot ocol with any/all amendments, all correspondence with and approval 
from the IRB/EC, the clinical trial agreement, the Investigator Agreement, device accountability records, 
individual subject records, signed informed consent forms  copies of signed and date d CRFs (or 
equivalent), records of AEs and ADEs reported to sponsor and final report (including any statistical 
analyses) . Subject files, other source data and essential documentation kept in the Investigator study 
files, must be kept for a period of no less than 2 years after the latter of the following two dates: the 
date on which this investigation is terminated or comple ted. Records may need to be maintained by the 
Principal Investigator for a longer duration if national regulations require or if agreed to in writing with 
Medtronic. All data and documents should be made available if requested by relevant authorities.  
15.8.  Publication and Use of Information  
The Medtronic Publication and Authorship Policy is aligned with the International Committee of Medical 
Journal Editors (ICMJE) recommendations (www.icmje.org). Medtronic will seek to publish, in 
appropriate peer -reviewed jou rnals and scientific conferences, results of clinical studies where human 
subjects are involved, regardless of outcome. While study results are owned by Medtronic, all data on 
which a publication is based will be made available to all authors as required f or their participation in 
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 52 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  the publication process. Furthermore, data may be published or used by study investigators provided 
that such publication or use is in accordance with this this protocol, the Medtronic Publication and 
Authorship Policy, and the Cl inical Investigation Agreement. Investigators must submit a copy of all 
manuscripts and/or abstracts to Medtronic for review and comment 30 days prior to planned 
submission. Medtronic acknowledges that its right to review and comment shall relate solely to  the 
proprietary, licensing, and/or confidential rights Medtronic may have in such proposed publication, 
rather than whether such results and/or opinions are favorable to Medtronic.  
The publication of post -hoc analyses, regional results, or single -center e xperiences based on multicenter 
clinical studies should not precede that of the primary multicenter publication, and should cite the 
primary publication whenever possible, as required by specific journal and scientific meeting guidelines.  
Medtronic involv ement in a publication (e.g., funding of the study; sponsor of the study; collection, 
analysis, and interpretation of data; professional writing assistance) must be disclosed according to 
journal -specific policies, submission requirements, and prevailing e ditorial standards, in addition to 
those specified by International Committee of Medical Journal Editors. Authors must ensure that an 
acknowledgement/disclosure statement is included in the body of the manuscript for Medtronic to 
review for accuracy. All a uthors must also disclose financial or personal affiliations that could be 
considered conflicts of interest as per journal/conference requirements.  
To enable health care providers, payers, and subjects access to the wealth of Medtronic’s research, 
Medtroni c will report its scientific data in accordance with the principles outlined in the Guidance 
Document on Registration and Reporting Results of Company -Sponsored Clinical Trials under FDAAA 
2007 (Title VIII).  
15.9.  Suspension or Early Termination  
Medtronic or app ropriate regulatory authorities reserve the right to suspend or discontinue the study at 
any stage, with written notice to all investigators, all institutions, all reviewing IRBs (US A), any 
investigator(s) in communication with the EC (EU) , all subjects a nd subjects’ personal physicians and any 
applicable regulatory agencies. Similarly, investigators may withdraw from the study at any time, subject 
to providing written notification to Medtronic 30 days prior to the date they intend to withdraw. 
However, Me dtronic and investigators will be bound by their obligation to complete the follow -up of 
subjects already enrolled in the study. The subjects must be followed according to the clinical protocol, 
and information obtained during subject follow -up shall be re ported to Medtronic on the appropriate 
eCRF.  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 53 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  16. References  
1. Abolhoda A, Liu D, Brooks A, Burt M. Prolonged air leak following radical upper lobectomy: an 
analysis of incidence and possible risk factors. Chest. 1998;113(6):1507 -10.  
2. Brun elli A, Monteverde M, Borri A, Salati M, Marasco RD, Fianchini A. Predictors of prolonged air 
leak after pulmonary lobectomy. Ann Thorac Surg. 2004;77(4):1205 -10; discussion 10. 
doi:10.1016/j.athoracsur.2003.10.082.  
3. Ciccone AM, Meyers BF, Guthrie TJ, Davis GE, Yusen RD, Lefrak SS et al. Long -term outcome of 
bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thorac 
Cardiovasc Surg. 2003;125(3):513 -25. doi:10.1067/mtc.2003.147.  
4. Kaiser LR, Bavaria JE. Complications of thoraco scopy. Ann Thorac Surg. 1993;56(3):796 -8.  
5. Okereke I, Murthy SC, Alster JM, Blackstone EH, Rice TW. Characterization and importance of air 
leak after lobectomy. Ann Thorac Surg. 2005;79(4):1167 -73. 
doi:10.1016/j.athoracsur.2004.08.069.  
6. Rena O, Papali a E, Mineo TC, Massera F, Pirondini E, Turello D et al. Air-leak management after 
upper lobectomy in patients with fused fissure and chronic obstructive pulmonary disease: a 
pilot trial comparing sealant and standard treatment. Interact Cardiovasc Thorac S urg. 
2009;9(6):973 -7. doi:10.1510/icvts.2009.202770.  
7. Shikora SA, Kim JJ, Tarnoff ME. Reinforcing gastric staple -lines with bovine pericardial strips may 
decrease the likelihood of gastric leak after laparoscopic Roux -en-Y gastric bypass. Obes Surg. 
2003 ;13(1):37 -44. doi:10.1381/096089203321136566.  
8. Christou N, Efthimiou E. Five -year outcomes of laparoscopic adjustable gastric banding and 
laparoscopic Roux -en-Y gastric bypass in a comprehensive bariatric surgery program in Canada. 
Can J Surg. 2009;52(6) :E249 -58.  
9. Committee ACI. Updated position statement on sleeve gastrectomy as a bariatric procedure. 
Surg Obes Relat Dis. 2012;8(3):e21 -6. doi:10.1016/j.soard.2012.02.001.  
10. Abd Ellatif ME, Abdallah E, Askar W, Thabet W, Aboushady M, Abbas AE et al. L ong term 
predictors of success after laparoscopic sleeve gastrectomy. Int J Surg. 2014;12(5):504 -8. 
doi:10.1016/j.ijsu.2014.02.008.  
11. Parikh M, Issa R, McCrillis A, Saunders JK, Ude -Welcome A, Gagner M. Surgical strategies that 
may decrease leak after la paroscopic sleeve gastrectomy: a systematic review and meta -analysis 
of 9991 cases. Ann Surg. 2013;257(2):231 -7. doi:10.1097/SLA.0b013e31826cc714.  
12. Chekan E, Whelan RL. Surgical stapling device -tissue interactions: what surgeons need to know 
to improve patient outcomes. Med Devices (Auckl). 2014;7:305 -18. doi:10.2147/MDER.S67338.  
13. Akiyoshi T, Ueno M, Fukunaga Y, Nagayama S, Fujimoto Y, Konishi T et al. Incidence of and risk 
factors for anastomotic leakage after laparoscopic anterior resection with int racorporeal rectal 
transection and double -stapling technique anastomosis for rectal cancer. Am J Surg. 
2011;202(3):259 -64. doi:10.1016/j.amjsurg.2010.11.014.  
17.  Version History  
Version  Summary of Changes  Author(s)/Title  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 54 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  1.0 • ‘Not Applicable, New Document’  Nicholas Paquette,  
Senior Medical Writer  
2.0 • Removed Multi -use (MULU) Signa reloads 
from plan, replaced with single use reloads 
(Endo GIA™  Reloads with Tri-Staple™  
Technology and Tri -Staple™ 2.0 Intelligent 
Reloads)  
• Removed clinician questionnaire  
• Added  interim analysis  
• Update EU regions  Greg Sindberg  
Senior Medical Writer  
3.0 • Changed site language to “approximately 
10 sites in the USA and Europe (potentially 
in United Kingdom, Spain, Italy)” based on 
compliance recommendations  Greg Sindberg  
Senior Medical Writer  
 
  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 55 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  18. Appendices  
18.1.  APPENDIX A: Endo GIA™  with Tri -Staple™ Technology and 
Tri-Staple™ 2.0 Intelligent Reloads   
Endo GIA™  with Tri -Staple™ Technology and Tri -Staple™ 2.0 Intelligent Reloads  that are appropriate for 
use in this study:  
Standard 
Reload  EGIA45AV*  Gray  
EGIA45AVM  Tan  
EGIA45AMT  Purple  
EGIA60AVM  Tan  
EGIA60AMT  Purple  
Tri-Staple™ 2.0 
30 mm Reload  SIG30AV*  Gray  
SIG30AVM  Tan  
SIG30AMT  Purple  
Tri-Staple™ 2.0 
Curved Tip 
Reload  SIG30CTAV*  Gray  
SIG30CTAVM  Tan  
SIG45CTAV*  Gray  
SIG45CTAVM  Tan  
SIG45CTAMT  Purple  
SIG60CTAVM  Tan  
SIG60CTAMT  Purple  
Tri-Staple™ 2.0 
Radial Reload  SIGRADVM  Tan  
SIGRADMT  Purple  
SIGRADXT  Black  
Tri-Staple™ 2.0 
Black Reload  SIG45AXT  Black  
SIG60AXT  Black  
Endo GIA™ 
Reinforced 
Reload with 
Tri-Staple™ 
Technology  EGIATRS45AMT  Purple  
EGIATRS45AXT  Black  
EGIATRS60AMT  Purple  
EGIATRS60AXT  Black  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 56 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  18.2.  APPENDIX B: American Society of Anesthesiologists (ASA) 
Physical Status Grading System  
Last approved by the ASA House of Delegates on October 15, 2014  
https://www.asahq.org/resources/clinical -information/asa -physical -status -classification -system  
ASA PS 
Classification  Definition  Examples, including but not limited 
to: 
ASA I  A normal healthy patient  Healthy, non -smoking, no or minimal 
alcohol use  
ASA II  A patient with mild systemic 
disease  Mild diseases only without substantive 
functional limitations. Examples include 
(but not limited to):  current smoker, 
social alcohol drinker, pregnancy, 
obesity (30 < BMI < 40), well -controlled 
DM/HTN, mild lung disease  
ASA III  A patient with severe 
systemic disease  Substantive functional limitations; One or 
more moderate to severe diseases. 
Examples inc lude (but not limited to): 
poorly controlled DM or HTN, COPD, 
morbid obesity (BMI ≥40), active 
hepatitis, alcohol dependence or abuse, 
implanted pacemaker, moderate 
reduction of ejection fraction, ESRD 
undergoing regularly scheduled dialysis, 
premature inf ant PCA < 60 weeks, 
history (>3 months) of MI, CVA, TIA, or 
CAD/stents.  
ASA IV  A patient with severe 
systemic disease that is a 
constant threat to life  Examples include (but not limited to): 
recent ( <  3 months) MI, CVA, TIA, or 
CAD/stents, ongoing cardiac ischemia or 
severe valve dysfunction, severe 
reduction of ejection fraction, sepsis, 
DIC, ARD or ESRD not undergoing 
regularly scheduled dialysis  
ASA V  A moribund patient who is 
not expected to survi ve 
without the operation  Examples include (but not limited to): 
ruptured abdominal/thoracic aneurysm, 
massive trauma, intracranial bleed with 
mass effect, ischemic bowel in the face 
of significant cardiac pathology or 
multiple organ/system dysfunction  
ASA  VI A declared brain -dead 
patient whose organs are 
being removed for donor 
purposes   
 
  
Signia™ Stapling System using Endo GIA™ Reloads with Tri-Staple™ 
Technology and Tri -Staple™ 2.0 Intelligent Reloads Clinical 
Investigation Plan  
  
MDT17025SIG  Version  3.0 Page 57 of 57  
 
Medtronic Confidential  
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template  
  
  18.3.  APPENDIX C: List of Investigators and Institutions  
Investigational Sites information including addresses, contact information, Principal Investigators, their 
respective IRBs, and will be retained in a separate document from the body of the clinical investigation 
plan document. This will be provided to investigational sites and updated as necessar y. 
 